Microbial metabolite 4-ethylphenylsulfate (4EPS) interacts with AT1R, reduces blood pressure and outcome of AngII-induced aortic aneurysm

Harford, T.; Singh, K. D.; Pardhi, T. R.; Desnoyer, R.; Ravi, T.; Jara, Z. P.; Zalavadia, A.; Stenson, K.; Prasad, S. N. N.; Karnik, S. S.

doi:10.1101/2025.01.29.635371

bioRxiv · 10.1101/2025.01.29.635371

Microbial metabolite 4-ethylphenylsulfate (4EPS) interacts with AT1R, reduces blood pressure and outcome of AngII-induced aortic aneurysm

Harford, T.·Singh, K. D.·Pardhi, T. R.·Desnoyer, R.·Ravi, T.·Jara, Z. P.·Zalavadia, A.·Stenson, K.·Prasad, S. N. N.·Karnik, S. S.

View original source ↗Export metadata ↓

Abstract

BACKGROUNDPlasma accumulation of the gut microbial metabolite, 4-ethylphenylsulfate (4EPS), produced from dietary protein aromatic amino acids has been observed in correlative and associative studies of cardiovascular, renal, metabolic and neurological diseases. 4EPS level increases upon AngII infusion in mice. How 4EPS alters host physiology to contribute to progression of any disease state is currently unknown. METHODSTo test the hypothesis that 4EPS interferes with angiotensin binding to AT1R, we used multiple approaches: AT1R pharmacology, cell-signaling, ex vivo vascular contraction and a mouse model of angiotensin-induced aortic aneurysm (AA) disease. ApoE-null mice were fed high-fat diet and infused with AngII, or co-infused with 4EPS and Olmesartan. BP was recorded. At the end of infusion, aortas were assessed for severity of AA, contractile response and histopathology. To evaluate signaling associated with different AA outcomes plasma proteomics analysis was done. RESULTSIn vitro, 4EPS reduced the binding of angiotensin and Candesartan to AT1R and calcium signaling. Ex vivo, 4EPS decreased vasomotor response of the aorta to AngII. In vivo, 4EPS inhibited AngII-mediated increase of BP and reduced mortality from AA. Abdominal aorta remodeling in 4EPS+AngII co-infused mice showed an increase of elastin area and reduced thickening of intimal/medial layers. Plasma proteome analysis indicated significant change in actin-cytoskeletal signaling associated with reduced ERK1/2 and Filamin-A activation, and cell motility. CONCLUSIONSBenign antagonism of AT1R by 4EPS involves direct interaction with AT1R. Molecular mechanisms of 4EPS responsible for reduced AA associated mortality in mice are distinct from those of AT1R blocker, Olmesartan. GRAPHIC ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=123 HEIGHT=200 SRC="FIGDIR/small/635371v1_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@1a33049org.highwire.dtl.DTLVardef@b73071org.highwire.dtl.DTLVardef@cd5557org.highwire.dtl.DTLVardef@9dc63e_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

pathology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Harford, T., Singh, K. D., Pardhi, T. R., Desnoyer, R., Ravi, T., Jara, Z. P., Zalavadia, A., Stenson, K., Prasad, S. N. N., Karnik, S. S.. 2025-02-02. Microbial metabolite 4-ethylphenylsulfate (4EPS) interacts with AT1R, reduces blood pressure and outcome of AngII-induced aortic aneurysm. https://doi.org/10.1101/2025.01.29.635371

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

bioRxiv2026

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗

bioRxiv2026

TREM2-stimulated, PDGF-dependent macrophage-fibroblast crosstalk induces beneficial plaque remodeling in clonal hematopoiesis

Background: In Jak2V617F clonal hematopoiesis, inflammatory signaling suppresses macrophage TREM2 and promotes features of plaque instability, while therapeutic TREM2 agonism reverses plaque instability by increasing fibroblasts and fibrous cap formation. We tested whether macrophage-derived PDGFB and stromal cell PDGFR? signaling mediate this response. Methods: Low allele burden (LAB) Jak2V617F atherosclerosis models were combined with inducible Pdgfb deletion in CX3CR1-lineage monocytes/macrophages or Pdgfra deletion in Col1a2-lineage fibroblast-enriched stromal cells. Mice were treated with the TREM2 agonist 4D9. Plaque composition, macrophage-fibroblast interactions, and aortic stromal cell populations were analyzed. Human WT and JAK2V617F iPSC-derived macrophages were used for validation. Results: TREM2 activation with 4D9 increased macrophage PDGFB production and promoted fibrous cap formation in LAB Jak2V617F atherosclerosis. Deletion of Pdgfb in CX3CR1-lineage cells markedly attenuated the 4D9-mediated increase in fibrous cap area and lesional PDGFR?+ cells, establishing macrophage-derived PDGFB as a key signal for the stromal response. Consistently, Col1a2-lineage Pdgfra deletion abolished the 4D9-induced fibrous cap response without significantly altering lesion or necrotic core area. Single cell RNA-seq identified increased Fmod+ and CD26/Dpp4+ fibroblast populations associated with 4D9 treatment. Fmod+ fibroblasts represented an abundant matrix-associated population, whereas CD26+ fibroblasts showed greatest enrichment, prominent extracellular matrix, collagen organization, and matrix-remodeling programs that were enhanced by 4D9 and attenuated by Pdgfra deletion. The stromal response was also associated with reduced macrophage migration-related programs and predicted chemokine communication from CD26+ fibroblasts to macrophages which was verified by macrophage migration studies. Moreover, stromal Pdgfra deletion increased lesional CCR2+ and CCR5+ macrophages. Conclusions: In a CH model of inflammatory atherosclerosis, TREM2 activation promotes a macrophage PDGFB-stromal PDGFR? pathway that expands Fmod+ and CD26+ fibroblast populations and increases fibrous cap matrix formation. CD26+ fibroblasts impair macrophage chemotaxis in a DPP4-dependent manner, suggesting reciprocal macrophage-fibroblast communication that coordinates matrix remodeling and inflammatory cell trafficking in the plaque.

pathology↗